M&As this week: BriaCell Therapeutics, Lentigen Technology
BriaCell Therapeutics plans to acquire Sapientia Pharmaceuticals through its subsidiary BriaCell Therapeutics (BriaCell USA).
BriaCell Therapeutics is a biotechnology company based in Canada, while Sapientia is a US-based biotechnology company.
The acquisition will enable BriaCell to expand its drug discovery capabilities and broaden its pipeline.
Miltenyi Biotec subsidiary Lentigen Technology has announced the acquisition of personalised chimeric antigen receptor (CAR) T-cell therapy developer, Living Pharma.
The acquisition will enable Lentigen to progress the development of its CAR T-cell therapies.
Both the target and the acquirer companies are based in the US.